Rembelska M J, Liniecki J
Nuklearmedizin. 1982 Apr;21(2):62-7.
A method was developed for labeling bleomycin with 51Cr. The complex was administered to mice (Swiss and C57-B1/6) bearing 5 transplantable tumours: Ehrlich ascites tumour, NK/Ly lymphoma, Lewis lung carcinoma, melanoma B-16, and Sarcoma 180. Activity concentration in neoplasms, blood and numerous organs was determined 12, 24 and 48 hrs after injection. An identical procedure was applied using 58Co-bleomycin as a reference oncophilic substance. Tumour/non-tumor ratios exceeding substantially unity were found for blood, muscle and bone indicating preferential accumulation of both 58Co and 51Cr in all the neoplasms tested. The ratios were lower (by a factor 2-3) for 51Cr than for 58Co; however, it is postulated that the gamma-quantum energy of 51Cr which is higher than that of the commonly used 57Co, should offset to some degree this difference when scintigraphic tumour detection in a patient is to be attempted. In conclusion, clinical trials with 51Cr-bleomycin, which is cheaper than its 57Co-counterpart, appear warranted.
已研发出一种用51Cr标记博来霉素的方法。将该复合物给予患有5种可移植肿瘤的小鼠（瑞士小鼠和C57-B1/6小鼠）：艾氏腹水瘤、NK/Ly淋巴瘤、刘易斯肺癌、黑色素瘤B-16和肉瘤180。在注射后12、24和48小时测定肿瘤、血液和许多器官中的活性浓度。使用58Co-博来霉素作为参考亲肿瘤物质采用相同的程序。发现血液、肌肉和骨骼的肿瘤/非肿瘤比率大大超过1，表明58Co和51Cr在所有测试肿瘤中均有优先蓄积。51Cr的比率比58Co低（2至3倍）；然而，据推测，51Cr的γ量子能量高于常用的57Co，在尝试对患者进行闪烁扫描肿瘤检测时，应能在一定程度上抵消这种差异。总之，使用比57Co标记的博来霉素更便宜的51Cr-博来霉素进行临床试验似乎是有必要的。
